Progestins induce catalase activities in breast cancer cells through PRB isoform: Correlation with cell growth inhibition

Journal of Steroid Biochemistry and Molecular Biology

Volumn 115, Issue 3-5, 2009, Pages 153-160

  Petit, Emile ^a   Courtin, Aurélie ^a   Kloosterboer, Helenius J ^b   Rostène, William ^c   Forgez, Patricia ^a   Gompel, Anne ^a,d  

^a SORBONNE UNIVERSITÉ   (France)

^b NV ORGANON   (Netherlands)

^c HÔPITAL SAINT ANTOINE   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Hydrogen peroxide; MPA; NETA; Normal breast cells; Progesterone; Tibolone

Indexed keywords

ANTIGESTAGEN; CATALASE; GESTAGEN; HYDROGEN PEROXIDE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PROGESTERONE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; TIBOLONE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DETOXIFICATION; DNA STRUCTURE; ENZYME ACTIVITY; GROWTH INHIBITION; HOMEOSTASIS; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

BREAST; BREAST NEOPLASMS; CATALASE; CELL LINE, TUMOR; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; HYDROGEN PEROXIDE; NORPREGNENES; OXIDANTS; PROGESTERONE; PROGESTINS; REACTIVE OXYGEN SPECIES; RECEPTORS, PROGESTERONE;

EID: 67349215107     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.04.002     Document Type: Article

References (40)

1. Burdon R.H. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic. Biol. Med. 18 4 (1995) 775-794
2. Sauer H., Wartenberg M., and Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell. Physiol. Biochem. 11 4 (2001) 173-186
3. Liu M., Pelling J.C., Ju J., Chu E., and Brash D.E. Antioxidant action via p53-mediated apoptosis. Cancer Res. 58 8 (1998) 1723-1729
4. Jones B.E., Lo C.R., Liu H., Pradhan Z., Garcia L., Srinivasan A., Valentino K.L., and Czaja M.J. Role of caspases and NF-kappaB signaling in hydrogen peroxide- and superoxide-induced hepatocyte apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 278 5 (2000) G693-G699
5. Bhunia A.K., Schwarzmann G., and Chatterjee S. GD3 recruits reactive oxygen species to induce cell proliferation and apoptosis in human aortic smooth muscle cells. J. Biol. Chem. 277 19 (2002) 16396-16402
6. Kim B.Y., Han M.J., and Chung A.S. Effects of reactive oxygen species on proliferation of Chinese hamster lung fibroblast (V79) cells. Free Radic. Biol. Med. 30 6 (2001) 686-698
7. Mann H., McCoy M.T., Subramaniam J., Van Remmen H., and Cadet J.L. Overexpression of superoxide dismutase and catalase in immortalized neural cells: toxic effects of hydrogen peroxide. Brain Res. 770 1-2 (1997) 163-168
8. Gupta A., Butts B., Kwei K.A., Dvorakova K., Stratton S.P., Briehl M.M., and Bowden G.T. Attenuation of catalase activity in the malignant phenotype plays a functional role in an in vitro model for tumor progression. Cancer Lett. 173 2 (2001) 115-125
9. Ray G., Batra S., Shukla N.K., Deo S., Raina V., Ashok S., and Husain S.A. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res. Treat. 59 2 (2000) 163-170
10. Brown N.S., and Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 3 5 (2001) 323-327
11. Ishii K., Zhen L.X., Wang D.H., Funamori Y., Ogawa K., and Taketa K. Prevention of mammary tumorigenesis in acatalasemic mice by vitamin E supplementation. Jpn. J. Cancer Res. 87 7 (1996) 680-684
12. Ahn J., Gammon M.D., Santella R.M., Gaudet M.M., Britton J.A., Teitelbaum S.L., Terry M.B., Nowell S., Davis W., Garza C., Neugut A.I., and Ambrosone C.B. Associations between breast cancer risk and the catalase genotype, fruit and vegetable consumption, and supplement use. Am. J. Epidemiol. 162 10 (2005) 943-952
13. Quick S.K., Shields P.G., Nie J., Platek M.E., McCann S.E., Hutson A.D., Trevisan M., Vito D., Modali R., Lehman T.A., Seddon M., Edge S.B., Marian C., Muti P., and Freudenheim J.L. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 17 5 (2008) 1082-1087
14. Mobley J.A., and Brueggemeier R.W. Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis 25 1 (2004) 3-9
15. Cavalieri E., Frenkel K., Liehr J.G., Rogan E., and Roy D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J. Natl. Cancer Inst. Monogr. 27 (2000) 75-93
16. McGowan E.M., and Clarke C.L. Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells. Mol. Endocrinol. 13 10 (1999) 1657-1671
17. Gompel A., Malet C., Spritzer P., Lalardrie J.P., Kuttenn F., and Mauvais-Jarvis P. Progestin effect on cell proliferation and 17 beta-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J. Clin. Endocrinol. Metab. 63 5 (1986) 1174-1180
18. Gompel A., Chaouat M., Jacob D., Perrot J.Y., Kloosterboer H.J., and Rostene W. In vitro studies of tibolone in breast cells. Fertil. Steril. 78 2 (2002) 351-359
19. Quilliet X., Chevallier-Lagente O., Zeng L., Calvayrac R., Mezzina M., Sarasin A., and Vuillaume M. Retroviral-mediated correction of DNA repair defect in xeroderma pigmentosum cells is associated with recovery of catalase activity. Mutat. Res. 385 3 (1997) 235-242
20. 2 disproportionation in extracts from normal and xeroderma pigmentosum skins, and from normal, xeroderma pigmentosum, ataxia telangiectasia and simian virus 40 transformed cell lines. Carcinogenesis 10 8 (1989) 1375-1381
21. 2 increase in pre-neoplastic and neoplastic lesions of the human lower female genital tract and their near adjacent epithelia. Biomed. Pharmacother. 45 10 (1991) 435-444
22. Kandouz M., Siromachkova M., Jacob D., Chretien Marquet B., Therwath A., and Gompel A. Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells. Int. J. Cancer 68 1 (1996) 120-125
23. Buvet R. Energetics of the chemical coupling between ATP production and oxygen reduction. Comparison with electrochemical data. Bioelectrochem. Bioenerg. 9 (1982) 299-305
24. Darr D., and Fridovich I. Irreversible inactivation of catalase by 3-amino-1,2,4-triazole. Biochem. Pharmacol. 35 20 (1986) 3642
25. Wiebe J.P., Muzia D., Hu J., Szwajcer D., Hill S.A., and Seachrist J.L. The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res. 60 4 (2000) 936-943
26. Sutherland R.L., Prall O.W., Watts C.K., and Musgrove E.A. Estrogen and progestin regulation of cell cycle progression. J. Mammary Gland Biol. Neoplasia 3 1 (1998) 63-72
27. Vicent G.P., Ballare C., Zaurin R., Saragueta P., and Beato M. Chromatin remodeling and control of cell proliferation by progestins via cross talk of progesterone receptor with the estrogen receptors and kinase signaling pathways. Ann. N.Y. Acad. Sci. 1089 (2006) 59-72
28. Fournier A., Berrino F., Riboli E., Avenel V., and Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer 114 3 (2005) 448-454
29. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res. Treat. 107 1 (2008) 103-111
30. Rabilloud T., Asselineau D., Miquel C., Calvayrac R., Darmon M., and Vuillaume M. Deficiency in catalase activity correlates with the appearance of tumor phenotype in human keratinocytes. Int. J. Cancer 45 5 (1990) 952-956
31. Kloosterboer H.J., Schoonen W.G., Deckers G.H., and Klijn J.G. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J. Steroid Biochem. Mol. Biol. 49 4-6 (1994) 311-318
32. Steckelbroeck S., Jin Y., Oyesanmi B., Kloosterboer H.J., and Penning T.M. Tibolone is metabolized by the 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four human isozymes of the aldo-keto reductase 1C subfamily: inversion of stereospecificity with a delta5(10)-3-ketosteroid. Mol. Pharmacol. 66 6 (2004) 1702-1711
33. Schatz F., Kuczynski E., Kloosterboer H.J., Buchwalder L., Tang C., Krikun G., and Lockwood C.J. Tibolone and its metabolites enhance tissue factor and PAI-1 expression in human endometrial stromal cells: evidence of progestogenic effects. Steroids 70 12 (2005) 840-845
34. Tang B., Markiewicz L., Kloosterboer H.J., and Gurpide E. Human endometrial 3 beta-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14). J. Steroid Biochem. Mol. Biol. 45 5 (1993) 345-351
35. Botella J., Duranti E., Duc I., Cognet A.M., Delansorne R., and Paris J. Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. J. Steroid Biochem. Mol. Biol. 50 1-2 (1994) 41-47
36. Schoonen W.G., Deckers G.H., de Gooijer M.E., de Ries R., and Kloosterboer H.J. Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J. Steroid Biochem. Mol. Biol. 74 4 (2000) 213-222
37. Dabrosin C., Hammar M., and Ollinger K. Impact of oestradiol and progesterone on antioxidant activity in normal human breast epithelial cells in culture. Free Radic. Res. 28 3 (1998) 241-249
38. Azevedo-Martins A.K., and Curi R. Fatty acids decrease catalase activity in human leukaemia cell lines. Cell Biochem. Funct. 26 1 (2008) 87-94
39. Hopp T.A., Weiss H.L., Hilsenbeck S.G., Cui Y., Allred D.C., Horwitz K.B., and Fuqua S.A. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin. Cancer Res. 10 8 (2004) 2751-2760
40. Gompel A., and Courtin A. Progesterone receptor isoforms and human breast cancer. In: Pasqualini J.R. (Ed). Breast Cancer: Prognosis, Treatment and Prevention (2008), INFORMA-Healthcare, New York 113-122